Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VRDN-003 in active thyroid eye disease
NL-OMON60694Phase 3Active, not recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elegrobart in Graves Orbitopathy (GO) (3 arms), sponsored by Viridian Therapeutics. Primary endpoint: Overall Responder Rate at Week 24. Started Mar 2025; status: active, not recruiting.
02
Drugs
elegrobart
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NL-OMON60694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60694.